Tocilizumab
Cold Chain RequiredFDA Approved, EMA Approved
Contents
Description
Tocilizumab is a humanized monoclonal antibody that inhibits interleukin-6 (IL-6) receptor signaling. It is approved for giant cell arteritis and has shown efficacy in other forms of vasculitis and autoimmune conditions. The drug blocks both soluble and membrane-bound IL-6 receptors, reducing inflammatory responses.
Indications & Therapeutic Use
giant cell arteritis, medium-vessel vasculitis, systemic inflammatory conditions
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Tocilizumab — GNH India
71 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Actemra 162mg/0.9ml
162mg/0.9mlvialsCanada
ACTEMRA
162 MGsolutionCANADA
Actemra 162
162mg
Actemra 200mg/10ml
200mg/10mlvialsCanada
Actemra 200mg -AU
200mg/10mlvialsAustralia
Actemra 200mg
200mg/10mlvialsJapan
ACTEMRA 200mg Inj
200mg 10mlinjectionJapan
Actemra 200mg/10ml -Japan
200mg/10mlvialsJapan
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Tocilizumab
| Generic Name | tocilizumab |
| Brands | 1 brand available |
| Active Ingredient | tocilizumab |
| Drug Class | giant cell arteritis |
| Manufacturer | Genentech/Roche |
| Dosage Forms | IV infusion 20mg/mL; subcutaneous injection 162mg/0.9mL |
| Medical Code | L04AC07 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT01791153 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes